Inovio Biomedical's DNA Delivery Technology Significantly Enhances Potency of Gene-Based Prostate Cancer Vaccine
Key Milestone for First-in-Man DNA Vaccine Clinical Trial Using Inovio's Electroporation DNA Delivery Technology
The results demonstrated safety, tolerability and significantly higher antibody responses for patients who received the vaccine with Inovios delivery system versus those who were treated without it. Inovios electroporation-mediated DNA delivery system is designed to enhance the potency of DNA-based immunotherapies against cancers and infectious diseases.
An analysis of interim data from the first and partially from the second dose treatment groups demonstrated the following points:
1. Electroporation appears safe and it is well tolerated.
2. The number of patients with significant antibody responses was four of 10 in the patient groups treated without electroporation compared to nine of 10 in the patient groups treated with electroporation.
3. The magnitude of the antibody response was significantly higher in patients treated using electroporation. Data on the T-cell response is being compiled.
The investigators continue to enroll and treat patients in the higher-dosage treatment groups.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.